Contineum Therapeutics, Inc.

Contineum Therapeutics, Inc. (CTNM) priced its initial public offering on Apr 8, 2024 at $16.00 per share, raising $110M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $402.1M. Goldman Sachs was lead-left underwriter, joined by Morgan Stanley, Stifel and RBC Capital Markets. Gunderson Dettmer advised the company and Sidley Austin advised the underwriters.

Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing oral small molecule therapies for neuroscience, inflammation and immunology indications. Its lead asset, PIPE-791, is an LPA1R inhibitor in development for idiopathic pulmonary fibrosis and progressive multiple sclerosis.

Status

IPO

Ticker

CTNM

Exchange

Nasdaq Global Select

Priced

Apr 8, 2024

IPO price

$16.00

Raised

$110M

Market cap at IPO price

$402.1M

First filed

Mar 15, 2024

Underwriters

Goldman Sachs, Morgan Stanley, Stifel and RBC Capital Markets

Company counsel

Gunderson Dettmer

Underwriters' counsel

Sidley Austin

Sector

Biotech & pharma

Country / state

CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.